Healthcare merger and acquisition activity remained robust in the first quarter of 2024, with 29 transactions vs. 28 in 2023. Biopharma was the most active healthcare subsector, representing 45% of deal volume, while services activity remained dampened despite notable transactions such as Novo Holdings’ acquisition of Catalent. We expect biopharma M&A activity to remain robust as large pharmaceutical companies attempt to fill revenue and pipeline gaps via acquisitions of late- or commercial-stage…
Source link
La Potencia Mas Caliente